Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Rosetta Genomics, GTG sign exclusive distribution agreement

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, and Genetic Technologies Limited (GTG), the leading private genetic testing laboratory in Australia, announced today the signing of an exclusive distribution agreement for Rosetta Genomics’ three currently available diagnostic tests.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

21 Oct 2009

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.

20 Oct 2009

NCCN program on Discovery Health Channel profiles patients battling lung cancer

Lung cancer is the second most common cancer and leading cause of cancer-related deaths in both men and women. Although tobacco use is the strongest known risk factor for lung cancer, many people who never smoked also develop the disease.

19 Oct 2009

Prometheus Laboratories introduces three new cancer diagnostic products

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

15 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Geniom RT Analyzer provides accurate diagnosis of multiple sclerosis and lung cancer disorders

Data published in BMC Cancer and PLoS ONE show that microRNA (miRNA) biomarkers provide reliable and highly differentiated diagnosis from blood samples for lung cancer and multiple sclerosis.

14 Oct 2009

AACR to host its first Frontiers in Basic Cancer Research Meeting

The American Association for Cancer Research will host its first Frontiers in Basic Cancer Research Meeting in Boston from Oct. 8-11, 2009. The meeting is expected to draw nearly 500 leading scientists to present on high-profile topics like epigenetics, metastasis and systems biology, and create synergies among the many subfields of basic science.

12 Oct 2009

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs.

8 Oct 2009

NIH grants over $3.8 million to Asuragen

Asuragen, Inc. announced today that it has received over $3.8 million in new grant funding for 2009 from the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and American Recovery and Reinvestment Act (ARRA) funded initiatives of the National Institutes of Health (NIH) to further its development of molecular diagnostics for oncology and genetic disease.

8 Oct 2009

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Peregrine Pharmaceuticals, Inc. today announced that it has established a new Anti-Viral Research Group in its R&D organization.

7 Oct 2009

New lung cancer pathways discovered using computer modeling

Using computer modeling, the Translational Genomics Research Institute and Scottsdale Healthcare have discovered lung cancer 'pathways' that could become targets for new drugs, according to a scientific paper published online today by the Journal of Thoracic Oncology.

7 Oct 2009

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Helix BioPharma Corp. today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").

7 Oct 2009

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.

5 Oct 2009

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

Peregrine Pharmaceuticals, Inc. today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria.

5 Oct 2009

Researchers study the role of CHRNA3 and CHRNA5 genes in lung cancer

A recent study published in the October 2009 issue of the Journal of Thoracic Oncology determined that variations of specific genetic markers identified in previous research, or SNPs, may indicate a greater lung cancer risk in African Americans than in whites. The genes CHRNA3 and CHRNA5 may contribute to lung cancer risk due directly or through their association with nicotine dependence.

3 Oct 2009

Sagent announces launch of vinorelbine injection

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched vinorelbine injection, USP, an anti-mitotic chemotherapy drug. According to IMS, 2008 sales of vinorelbine injection, USP in the United States approximated $17 million. Sagent will begin marketing and shipping vinorelbine injection immediately.

3 Oct 2009

Telik's announces positive results from Phase 1-2a TELCYTA-carboplatin-paclitaxel combination study

Telik, Inc. today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10.

3 Oct 2009